Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drepaglobe
- Development stage
- Phase 1
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Recombinant Proteins and Enzymes, Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
Drepaglobe is an autologous gene therapy product developed for the treatment of sickle cell disease. It consists of a patient's own CD34+ hematopoietic stem cells that are collected and then transduced ex vivo with the GLOBE1 lentiviral vector encoding the βAS3 globin gene. The modified cells are infused back into the patient via intravenous administration. The therapeutic goal is to enable these genetically modified stem cells to engraft and produce red blood cells expressing functional hemoglobin, thereby reducing or eliminating sickling events and improving overall hemoglobin levels. Clinical studies have shown that patients treated with Drepaglobe experienced clinically meaningful improvements in total and fetal hemoglobin levels, as well as freedom from vaso-occlusive events for extended periods post-treatment[3][4][7].
- Brand names
- Drepaglobe
- Other names
- Cellules CD34+ modifiées par vecteur globe1beta AS3GLOBE1 lentiviral vector expressing βAS3 globin gene
02
Targets
Hb (Hemoglobin)
Beyond the preview
Go deeper on Drepaglobe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Drepaglobe.